ESCC
Clinical trials for ESCC explained in plain language.
Never miss a new study
Get alerted when new ESCC trials appear
Sign up with your email to follow new studies for ESCC, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy aims to extend life in elderly esophageal cancer patients
Disease control Not yet recruitingThis study tests a chemotherapy drug (TAS-102) combined with radiation in people aged 65–85 with advanced esophageal cancer that has not spread to distant organs. The goal is to find the safest dose and see if the combination helps patients live longer and controls the cancer. Ab…
Matched conditions: ESCC
Phase: PHASE1, PHASE2 • Sponsor: Qianfoshan Hospital • Aim: Disease control
Last updated Jun 16, 2026 12:49 UTC
-
New drug duo aims to shrink esophageal tumors before surgery
Disease control Not yet recruitingThis study tests whether a new combination of drugs (iparomlimab and tuvonralimab) plus chemotherapy can shrink tumors before surgery in people with a certain type of esophageal cancer. The goal is to see if this approach helps remove all cancer cells and improves long-term outco…
Matched conditions: ESCC
Phase: PHASE2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Jun 15, 2026 19:07 UTC
-
New drug cocktail aims to shrink esophageal tumors before surgery
Disease control Not yet recruitingThis study tests whether giving three drugs (adebrelimab, nimotuzumab, and chemotherapy) before surgery can help people with a type of esophageal cancer. About 22 adults with resectable tumors will receive two cycles of the combination, then have surgery. The main goal is to see …
Matched conditions: ESCC
Phase: NA • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Jun 15, 2026 19:06 UTC
-
New drug cocktail aims to shrink tough esophageal tumors
Disease control Not yet recruitingThis study tests a new drug called QL1706, which boosts the immune system, together with two chemotherapy drugs (nab-paclitaxel and cisplatin) as the first treatment for people with advanced or metastatic esophageal squamous cell carcinoma. The goal is to see if this combination …
Matched conditions: ESCC
Phase: PHASE2 • Sponsor: The First Affiliated Hospital of Henan University of Science and Technology • Aim: Disease control
Last updated Jun 15, 2026 19:03 UTC
-
New hope for esophageal cancer patients who failed immunotherapy
Disease control Not yet recruitingThis study tests a combination of two drugs, SHR-1701 and liposomal irinotecan, in 33 adults with esophageal squamous cell carcinoma who have already received immunotherapy. The goal is to see if the combo can shrink tumors or stop them from growing. Participants will receive the…
Matched conditions: ESCC
Phase: PHASE2 • Sponsor: Zhigang Li • Aim: Disease control
Last updated Jun 15, 2026 19:03 UTC
-
Could a drug combo let some esophageal cancer patients skip surgery?
Disease control Not yet recruitingThis study tests a drug called adebrelimab combined with chemotherapy before deciding on surgery for people with a certain type of esophageal cancer. About 200 participants will receive the treatment first. If the cancer disappears completely on scans, they will be randomly assig…
Matched conditions: ESCC
Phase: PHASE2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Jun 15, 2026 19:02 UTC
-
New triple therapy hopes to outsmart tough esophageal cancer
Disease control Not yet recruitingThis study tests a new combination of three drugs—becotatug vedotin, tislelizumab, and chemotherapy—for people with advanced esophageal squamous cell carcinoma (ESCC) who have not had prior treatment. The goal is to see if adding the targeted drug becotatug vedotin to standard im…
Matched conditions: ESCC
Phase: PHASE2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Jun 15, 2026 18:57 UTC